Answers are grounded in this paper and cite their sources.
These results demonstrate that pertuzumab is well tolerated, has a pharmacokinetic profile which supports 3-week dosing, and is clinically active, suggesting that inhibition of dimerization may be an effective anticancer strategy.
No takes yet. Share an insight, caveat, or question.
Agus et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: